Frontlight ResearchEarly access
IgA nephropathy trials in Czechia
7 of 7 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Where
- Nový Jičín, Olomouc, Prague
- Age
- 18 years and over
- People
- 347 worldwide
- Run by
- Takeda
See details and how to joinNCT06963827 · EU 2025-520825-19-00 - Phase 3Taking peopleA clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have completed previous zigakibart trials
- Where
- Prague
- Age
- 18 years and over
- People
- 69 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-519638-22-00 - Phase 2Not yet taking people in CzechiaA Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
- Where
- Hradec Králové, Praha 2
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- argenx
See details and how to joinNCT07773727 · EU 2026-525638-43-00 - Phase 2Not yet taking people in CzechiaA Study to Assess the Effects of Zigakibart on IgA Nephropathy.
- Where
- Prague
- Age
- 18 years and over
- People
- 32 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07146906 · EU 2024-519699-24-00 - Phase 3Taking peopleA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- Where
- Prague
- Age
- 18 years and over
- People
- 454 worldwide
- Run by
- Biogen
See details and how to joinNCT06935357 · EU 2024-519345-30-00 - Phase 3Active, not recruitingA Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- Where
- Prague
- Age
- 18 years to 100 years
- People
- 540 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00 - Phase 2/3Enrolling by invitationTrial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
- Where
- Prague
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Otsuka Pharmaceutical Development & Commercialization, Inc.
See details and how to joinNCT05248659